307(top 1%)
publications
30.2K
citations
72(top 1%)
h-index
6.25(top 1%)
e-Score
3.3K
citing journals
100
times ranked

Publications

307 publications • 30,168 citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleYearIFCitationsLinks
1Low-Dose Colchicine Attenuates Clonal Hematopoiesis in COLCOT.
Circulation, 153, 610-612
202624.78Citations (PDF)
2Timing of Statin Dose: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.20226.23Citations (PDF)
3Pharmacogenetics-Guided Dalcetrapib Therapy After an Acute Coronary Syndrome: The Dal-GenE Trial
European Heart Journal, 43, 3947-3956
202214.837Citations (PDF)
4Myocardial Infarction in the ISCHEMIA Trial
Circulation, 143, 790-804
202124.7135Citations (PDF)
5Cost-Effectiveness of Low-Dose Colchicine After Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)20214.977Citations (PDF)
6Notes From Cardiology Clinic: Trouble for Tongans20213.81Citations (PDF)
7Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT20214.017Citations (PDF)
8The Association Between Lipid Levels and Leukocyte Count: A Cross-Sectional and Longitudinal Analysis of Three Large Cohorts20212.112Citations (PDF)
9Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib20214.010Citations (PDF)
10Notes From Cardiology Clinic: Mitral Stenosis and Racial Discordance20213.80Citations (PDF)
11Notes From Cardiology Clinic: Cinderella’s Electronic Medical Record20213.80Citations (PDF)
12Changing the Face of Cardiovascular Trial Participation: Moving Beyond Middle-Aged White Guys
CJC Open, 3, S1-S3
20211.81Citations (PDF)
13Usefulness of Angina to Guide Revascularization Decisions
Circulation, 144, 524-527
202124.71Citations (PDF)
14Notes From Cardiology Clinic: You Can't Ride With the Cops, but Cheer for the Robbers20213.80Citations (PDF)
15Colchicine for Community-Treated Patients With COVID-19 (COLCORONA): A Phase 3, Randomised, Double-Blinded, Adaptive, Placebo-Controlled, Multicentre Trial202128.0293Citations (PDF)
16Notes From Cardiology Clinic: The Patients We Dislike20203.80Citations (PDF)
17Notes From Cardiology Clinic: The Patients We Dislike.20203.80Citations (PDF)
18When Diastole Lets You Down: Clinical Relevance of a Widened Pulse Pressure20203.81Citations (PDF)
19Notes From Cardiology Clinic: Health Care Heroine, Unpaid and Unappreciated20203.80Citations (PDF)
20Notes From Cardiology Clinic: The Heartbreaking Risk Factor We Overlook20203.80Citations (PDF)
21Time-to-Treatment Initiation of Colchicine and Cardiovascular Outcomes After Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
European Heart Journal, 41, 4092-4099
202014.8307Citations (PDF)
22Will Colchicine Soon Be Part of Primary and Secondary Cardiovascular Prevention?20203.87Citations (PDF)
23Notes From the Cardiology Clinic: Facing Down the Dragons of Health Anxiety20203.80Citations (PDF)
24Notes From Cardiology Clinic: Brittle Bones and Blue Sclerae20203.80Citations (PDF)
25Study Design of Dal-GenE, a Pharmacogenetic Trial Targeting Reduction of Cardiovascular Events With Dalcetrapib20203.430Citations (PDF)
26Inflammation in Cardiovascular Disease: From Basic Concepts to Clinical Application20200.51Citations (PDF)
27Cholesterol Lowering Guidelines: From Whence We Came and Where We Are Now20193.87Citations (PDF)
28Improving Statin Noncompliance: If You Build It, Will They Come?20193.84Citations (PDF)
29Notes From Cardiology Clinic: When Our Responsibilities Extend Beyond the Patient20193.81Citations (PDF)
30Notes From Cardiology Clinic: Woman, Lost During Follow-Up.20193.80Citations (PDF)
31HIV Infection and Coronary Heart Disease: Mechanisms and Management201962.6210Citations (PDF)
32Atorvastatin Has a Dose‐Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double‐Blind Randomized Controlled Trials20195.830Citations (PDF)
33Introduction to Cardiovascular Issues in HIV20193.81Citations (PDF)
34Efficacy and Safety of Low-Dose Colchicine After Myocardial Infarction201976.83,055Citations (PDF)
35Lipid Abnormalities in Persons Living With HIV Infection20193.866Citations (PDF)
36High Plasma FGF21 Levels Predicts Major Cardiovascular Events in Patients Treated With Atorvastatin (From the Treating to New Targets [TNT] Study)201916.035Citations (PDF)
37Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial
Circulation, 138, 770-781
201824.7179Citations (PDF)
38Relationship of High‐Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin20185.87Citations (PDF)
39Visit-to-Visit Variability of Lipid Measurements as Predictors of Cardiovascular Events20184.757Citations (PDF)
40Variations in Time to Benefit Among Clinical Trials of Cholesterol-Lowering Drugs20184.730Citations (PDF)
41Lipids, Inflammation, and Chronic Kidney Disease: A SHARP Perspective201812.97Citations (PDF)
42Effect of Atorvastatin, Cholesterol Ester Transfer Protein Inhibition, and Diabetes Mellitus on Circulating Proprotein Subtilisin Kexin Type 9 and Lipoprotein(a) Levels in Patients at High Cardiovascular Risk20184.758Citations (PDF)
43RE: Praluent (Alirocumab)-Induced Renal Injury20181.31Citations (PDF)
44Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus20185.672Citations (PDF)
45Time to Recognize HIV Infection as a Major Cardiovascular Risk Factor
Circulation, 138, 1113-1115
201824.7110Citations (PDF)
46PCSK9 Inhibition to Reduce Cardiovascular Risk
Circulation Research, 120, 1537-1539
201715.716Citations (PDF)
47Body-Weight Fluctuations and Outcomes in Coronary Disease201776.8289Citations (PDF)
48An Evidence-Based Guide to Cholesterol-Lowering Guidelines20173.818Citations (PDF)
49Taking Hockey to Heart: Potential Coronary Risks of Watching Exciting Games20173.82Citations (PDF)
50Heart Failure in Persons Living With HIV Infection20173.641Citations (PDF)
51Are Cholesterol Treatment Targets a Deterrent to Optimal Lipid-Lowering Therapy?
JAMA Cardiology, 2, 1392-1393
201716.41Citations (PDF)
52The Evolution of Myocardial Infarction: When the Truths We Hold to Be Self-Evident No Longer Have Evidence20173.84Citations (PDF)
53Body-Weight Fluctuations and Outcomes in Coronary Disease201776.818Citations (PDF)
54The Rise and Fall of Tuberculosis and Atherosclerosis: First There Is a Mountain…20173.84Citations (PDF)
55Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction From the IDEAL Trial20172.566Citations (PDF)
56Tribulations of Recent Cardiology Trials, the Audacity of Hope, and HOPE-320163.81Citations (PDF)
57PCSK9 Inhibitors for Statin Intolerance?201637.221Citations (PDF)
58Metabolic Markers to Predict Incident Diabetes Mellitus in Statin-Treated Patients (From the Treating to New Targets and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trials)20162.518Citations (PDF)
59Performance Deficiencies in the Treatment of ST-Elevation Myocardial Infarction in Québec: “Tis but a Part We See, and Not a Whole”
Canadian Journal of Cardiology, 32, 1294.e5-1294.e7
20163.80Citations (PDF)
60Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (From the Treating to New Targets [TNT] Study).20162.58Citations (PDF)
612013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?20163.246Citations (PDF)
62Predicting Prognosis in Acute Coronary Syndromes: Makeover Time for TIMI and GRACE?20163.89Citations (PDF)
63Statin-Centric Versus Low-Density Lipoprotein-Centric Approach for Atherosclerotic Cardiovascular Disease Prevention: A Singapore Perspective.20161.68Citations (PDF)
64LDL-Cholesterol Lowering and Renal Outcomes20155.014Citations (PDF)
65Doctors' Knowledge, Attitudes, and Compliance With 2013 ACC/AHA Guidelines for Prevention of Atherosclerotic Cardiovascular Disease in Singapore20153.729Citations (PDF)
66Risk of New-Onset Diabetes and Cardiovascular Risk Reduction From High-Dose Statin Therapy in Pre-Diabetics and Non–Pre-Diabetics: An Analysis From TNT and IDEAL201512.140Citations (PDF)
67Impact of Female Sex on Lipid Lowering, Clinical Outcomes, and Adverse Effects in Atorvastatin Trials20152.557Citations (PDF)
68Reply: Statin-Induced Low Low-Density Lipoprotein Cholesterol Level: Is Lower Better?201512.11Citations (PDF)
69The Effect of Statin Therapy on Heart Failure Events: A Collaborative Meta-Analysis of Unpublished Data From Major Randomized Trials.201514.8155Citations (PDF)
70PCSK9 Inhibition to Lower LDL-Cholesterol and Reduce Cardiovascular Risk201515.79Citations (PDF)
71HMG-Coenzyme A Reductase Inhibition, Type 2 Diabetes, and Bodyweight: Evidence From Genetic Analysis and Randomised Trials
Lancet, The, 385, 351-361
201597.2619Citations (PDF)
72Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers
PLoS ONE, 9, e114519
20143.245Citations (PDF)
73TNT Trial20140Citations (PDF)
74TNT Trial20140Citations (PDF)
75The Past and Future of Heart Institutes: Having Moved Beyond the One-Trick Pony20143.84Citations (PDF)
76Cardiovascular Drugs That Increase the Risk of New-Onset Diabetes20143.433Citations (PDF)
77Impact of High-Dose Atorvastatin Therapy and Clinical Risk Factors on Incident Aortic Valve Stenosis in Patients With Cardiovascular Disease (From TNT, IDEAL, and SPARCL)20142.529Citations (PDF)
78Looking for Coronary Disease in Patients With Atrial Fibrillation20143.86Citations (PDF)
79Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events: A Meta-Analysis of Statin Trials201412.1568Citations (PDF)
80The Curse of Target Lesion Calcification: Still Active After All These Years.201412.15Citations (PDF)
81Statin and the Risk of Renal-Related Serious Adverse Events: Analysis From the IDEAL, TNT, Cards, Aspen, SPARCL, and Other Placebo-Controlled Trials20142.539Citations (PDF)
82Effect of Change in Body Weight on Incident Diabetes Mellitus in Patients With Stable Coronary Artery Disease Treated With Atorvastatin (From the Treating to New Targets Study)20142.527Citations (PDF)
83Meta-Analyses of Statin Trials: Clear Benefit for Primary Prevention in the Elderly∗201312.12Citations (PDF)
84Papering Over the Cracks: Meta-Analysis to Define the Role of Percutaneous Coronary Intervention in Patients With Stable Angina20133.81Citations (PDF)
85Reply: To PMID 23219296.201312.15Citations (PDF)
86Cardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy: Effect of Baseline Risk Factors for Diabetes.201312.1170Citations (PDF)
87Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy
Circulation, 125, 1979-87
201224.7165Citations (PDF)
88Utility of Biomarkers and Imaging in the Development of Drugs for the Treatment of Coronary Atherosclerosis20123.83Citations (PDF)
89Relation of Improvement in Estimated Glomerular Filtration Rate With Atorvastatin to Reductions in Hospitalizations for Heart Failure (From the Treating to New Targets [TNT] Study)20122.519Citations (PDF)
90Inhibition of Secretory Phospholipase A2 in Patients With Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial20124.141Citations (PDF)
91Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin: Results From 3 Large Randomized Clinical Trials.201112.1317Citations (PDF)
92Tobacco Smoke and Cardiovascular Risk: A Call for Continued Efforts to Reduce Exposure20112.214Citations (PDF)
93On-Treatment Lipoprotein Components and Risk of Cerebrovascular Events in the Treating to New Targets Study20114.410Citations (PDF)
94Hemodynamic and Arrhythmogenic Effects of Cocaine in Hypertensive Individuals20113.019Citations (PDF)
95Impact of Smoking on Cardiovascular Events in Patients With Coronary Disease Receiving Contemporary Medical Therapy (From the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trials)20112.558Citations (PDF)
96Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A1c in Subjects in the Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events (ILLUMINATE) Trial
Circulation, 124, 555-62
201124.7190Citations (PDF)
97Exploring New Indications for Statins Beyond Atherosclerosis: Successes and Setbacks20103.926Citations (PDF)
98Usefulness of Heart Rate at Rest as a Predictor of Mortality, Hospitalization for Heart Failure, Myocardial Infarction, and Stroke in Patients With Stable Coronary Heart Disease (Data From the Treating to New Targets [TNT] Trial).20102.577Citations (PDF)
99Statins Before Stents: Does an Ounce of Prevention Improve Outcomes?20103.80Citations (PDF)
100Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients With Congestive Heart Failure and Coronary Heart Disease in the US20105.818Citations (PDF)
101Lipid Treatment Assessment Project 2
Circulation, 120, 28-34
200924.7291Citations (PDF)
102Clinical Insights From the Treating to New Targets Trial20099.76Citations (PDF)
103Early Statin Therapy in Acute Coronary Syndromes: The Successful Cycle of Evidence, Guidelines, and Implementation.200912.121Citations (PDF)
104A Winter’s Tale: Report From the First Annual Canadian Biomarkers and Surrogate Endpoints Symposium20093.83Citations (PDF)
105Effects of 1-H-Indole-3-Glyoxamide (A-002) on Concentration of Secretory Phospholipase A2 (PLASMA Study): A Phase II Double-Blind, Randomised, Placebo-Controlled Trial
Lancet, The, 373, 649-658
200997.2114Citations (PDF)
106Preventing and Treating Stroke and Transient Ischemic Attack20082.51Citations (PDF)
107Comparison of Effectiveness of Atorvastatin 10 mg Versus 80 mg in Reducing Major Cardiovascular Events and Repeat Revascularization in Patients With Previous Percutaneous Coronary Intervention (Post Hoc Analysis of the Treating to New Targets [TNT] Study)20082.541Citations (PDF)
108Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery.200812.191Citations (PDF)
109The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and Baseline Characteristics200811.162Citations (PDF)
110Inflammation, Statin Therapy, and Risk of Stroke After an Acute Coronary Syndrome in the MIRACL Study20087.964Citations (PDF)
111Does Prevalence of the Metabolic Syndrome in Women With Coronary Artery Disease Differ by the ATP III and IDF Criteria?20082.122Citations (PDF)
112TNT Trial20080Citations (PDF)
113Effects of Torcetrapib in Patients at High Risk for Coronary Events200776.83,031Citations (PDF)
114The SPARCL Study: Extending the Indications of Statin Therapy for Stroke?20078.40Citations (PDF)
115Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure
Circulation, 115, 576-83
200724.7157Citations (PDF)
116The Editor’s Roundtable: Statin Therapy in Acute Coronary Syndrome20072.52Citations (PDF)
117Cardiac Arrest in Patients Who Smoke Crack Cocaine20072.539Citations (PDF)
118Treatment of Cardiovascular Manifestations of HIV20073.00Citations (PDF)
119Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients With Stable Coronary Disease in the TNT (Treating to New Targets) Study200612.163Citations (PDF)
120Effects of Statin Therapy on the Development and Progression of Heart Failure: Mechanisms and Clinical Trials20065.037Citations (PDF)
121What the Statin Trials Have Taught Us20062.529Citations (PDF)
122Increased Carotid Intima-Media Thickness in HIV Patients Is Associated With Increased Cytomegalovirus-Specific T-Cell Responses
Aids, 20, 2275
20062.7256Citations (PDF)
123Usefulness of Serum Endothelin Levels in Predicting Death and Myocardial Infarction but Not Coronary Progression in Postmenopausal Women With Coronary Disease (From the Women’s Angiographic Vitamin and Estrogen [WAVE] Study)20052.57Citations (PDF)
124Safety of High-Dose Atorvastatin Therapy20052.572Citations (PDF)
125Chlamydia pneumoniae and Atherosclerosis: From Koch Postulates to Clinical Trials20059.724Citations (PDF)
126What a Cardiologist Needs to Know About Patients With Human Immunodeficiency Virus Infection
Circulation, 112, 3947-57
200524.749Citations (PDF)
127High-Density Lipoprotein, but Not Low-Density Lipoprotein Cholesterol Levels Influence Short-Term Prognosis After Acute Coronary Syndrome: Results From the MIRACL Trial.200514.8192Citations (PDF)
128Hormone Therapy and Antioxidant Vitamins Do Not Improve Endothelial Vasodilator Function in Postmenopausal Women With Established Coronary Artery Disease: A Substudy of the Women's Angiographic Vitamin and Estrogen (WAVE) Trial
Atherosclerosis, 179, 193-200
20057.049Citations (PDF)
129Clinical Features of Acute Coronary Syndromes in Patients With Human Immunodeficiency Virus Infection
Circulation, 109, 316-9
200424.7190Citations (PDF)
130Progression of Atherosclerosis as Assessed by Carotid Intima-Media Thickness in Patients With HIV Infection
Circulation, 109, 1603-8
200424.7564Citations (PDF)
131Postmenopausal Hormone Therapy Is Associated With Atherosclerosis Progression in Women With Abnormal Glucose Tolerance
Circulation, 110, 201-6
200424.743Citations (PDF)
132Role of Thrombotic and Fibrinolytic Factors in Acute Coronary Syndromes20049.735Citations (PDF)
133Treating to New Targets (TNT) Study: Does Lowering Low-Density Lipoprotein Cholesterol Levels Below Currently Recommended Guidelines Yield Incremental Clinical Benefit?20042.5185Citations (PDF)
134Soluble Fibrin, C-Reactive Protein, Fibrinogen, Factor VII, Antithrombin, Proteins C and S, Tissue Factor, d-Dimer, and Prothrombin Fragment 1 + 2 in Men With Acute Myocardial Infarction ≤45 Years of Age20042.515Citations (PDF)
135Management of the Acute Coronary Syndrome Patient20043.00Citations (PDF)
136Lessons From the PROVE-IT Trial. Higher Dose of Potent Statin Better for High-Risk Patients.20042.414Citations (PDF)
137Management of the Acute Coronary Syndrome Patient20043.00Citations (PDF)
138Pharmacoeconomic Evaluation of the Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes20032.518Citations (PDF)
139Statins and Safety: Applying the Results of Randomized Trials to Clinical Practice20032.511Citations (PDF)
140Implications of Cigarette Smoking for the Management of Patients With Acute Coronary Syndromes20039.720Citations (PDF)
141Differences in Medical Care and Disease Outcomes Among Black and White Women With Heart Disease
Circulation, 108, 1089-94
200324.7132Citations (PDF)
142Women Do Benefit From Lipid Lowering: Latest Clinical Trial Data20031.717Citations (PDF)
143Vitamins and Hormone Therapy for Coronary Atherosclerosis—Reply200337.20Citations (PDF)
144Impact of Diabetes on the Risk Stratification Using Stress Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging in Patients With Symptoms Suggestive of Coronary Artery Disease
Circulation, 105, 32-40
200224.7354Citations (PDF)
145Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-Up (HERS II)200237.21,603Citations (PDF)
146Acute Aortic Dissection Related to Crack Cocaine
Circulation, 105, 1592-5
200224.7200Citations (PDF)
147Do Statins Confer Early Benefit After Acute Coronary Syndromes? The Results From FLORIDA.200214.81Citations (PDF)
148Effects of Atorvastatin on Stroke in Patients With Unstable Angina or Non-Q-Wave Myocardial Infarction
Circulation, 106, 1690-5
200224.7184Citations (PDF)
149Mechanical or Metabolic Treatment for Coronary Disease: Synergistic, Not Antagonistic, Approaches20021.73Citations (PDF)
150Effects of Hormone Replacement Therapy and Antioxidant Vitamin Supplements on Coronary Atherosclerosis in Postmenopausal Women: A Randomized Controlled Trial200237.2493Citations (PDF)
151Estrogen Therapy for Unstable Angina: Another Bump for the Bandwagon.200212.16Citations (PDF)
152Reassessment of National Cholesterol Education Program Adult Treatment Panel-III Guidelines: One Year Later.20022.52Citations (PDF)
153PRINCE’s Prospects: Statins, Inflammation, and Coronary Risk20013.420Citations (PDF)
154Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes: The MIRACL Study: A Randomized Controlled Trial200137.22,271Citations (PDF)
155Management of a Patient With Angina Pectoris
Chest, 119, 287-289
20015.90Citations (PDF)
156A Reply200114.80Citations (PDF)
157The Myocardial Ischemia Reduction With Acute Cholesterol Lowering (MIRACL) Trial: A New Frontier for Statins?
Trials, 2, 1-4
20012.620Citations (PDF)
158Are We Aggressive Enough in Lowering Cholesterol?20012.514Citations (PDF)
159What Is the Role of Intensive Cholesterol Lowering in the Treatment of Acute Coronary Syndromes?20012.514Citations (PDF)
160Early Pharmacologic Intervention and Plaque Stability in Acute Coronary Syndromes20012.514Citations (PDF)
161What Do the Statin Trials Tell Us?20013.18Citations (PDF)
162Low-Density-Lipoprotein Cholesterol Goals for Patients With Coronary Disease
Circulation, 104, 2635-7
200124.76Citations (PDF)
163Atorvastatin for Acute Coronary Syndromes200137.21Citations (PDF)
164Atorvastatin for Acute Coronary Syndromes—Reply200137.20Citations (PDF)
165Short- and Medium-Term Outcome Differences in Women and Men After Primary Percutaneous Transluminal Mechanical Revascularization for Acute Myocardial Infarction20002.524Citations (PDF)
166Comparison of Electrocardiographic-Gated Technetium-99m Sestamibi Single-Photon Emission Computed Tomographic Imaging and Rest-Redistribution Thallium-201 in the Prediction of Myocardial Viability20002.523Citations (PDF)
167Relation of C-Reactive Protein to Extent and Severity of Coronary Narrowing in Patients With Stable Angina Pectoris or Abnormal Exercise Tests20002.548Citations (PDF)
168Synergy Between Intracoronary Stenting and Abciximab in Improving Angiographic and Clinical Outcomes of Primary Angioplasty in Acute Myocardial Infarction20002.548Citations (PDF)
169Should Intensive Cholesterol Lowering Play a Role in the Management of Acute Coronary Syndromes?20002.56Citations (PDF)
170Introduction20002.58Citations (PDF)
171Is a Mechanical or a Metabolic Approach Superior in the Treatment of Coronary Disease? Results of the Atorvastatin Versus Revascularization (AVERT) Trial.200014.86Citations (PDF)
172Identification of Coronary Thrombus With a IIb/IIIa Platelet Inhibitor Radiopharmaceutical, Technetium-99m DMP-444
Circulation, 101, 1643-6
200024.735Citations (PDF)
173Postscripts From the Post Coronary Artery Bypass Graft Trial
Circulation, 102, 144-6
200024.713Citations (PDF)
174A Randomized Controlled Trial of Smoking Cessation Counseling After Myocardial Infarction
Preventive Medicine, 30, 261-268
20003.3161Citations (PDF)
175Error | American Heart Association Journals
Circulation, 102, 1-1
200024.72Citations (PDF)
176Aggressive Lipid-Lowering Therapy Compared With Angioplasty in Stable Coronary Artery Disease199976.8841Citations (PDF)
177Cholesterol Lowering
Circulation, 99, 3215-7
199924.726Citations (PDF)
178Functional Assessment With Electrocardiographic Gated Single-Photon Emission Computed Tomography Improves the Ability of Technetium-99m Sestamibi Myocardial Perfusion Imaging to Predict Myocardial Viability in Patients Undergoing Revascularization19992.571Citations (PDF)
179Impact of Limited Treadmill Exercise on Adenosine Tc-99m Sestamibi Single-Photon Emission Computed Tomographic Myocardial Perfusion Imaging in Coronary Artery Disease19992.534Citations (PDF)
180Clinical and Angiographic Characteristics of Exertion-Related Acute Myocardial Infarction199937.2171Citations (PDF)
181Combined Assessment of Myocardial Perfusion and Left Ventricular Function With Exercise Technetium-99m Sestamibi Gated Single-Photon Emission Computed Tomography Can Differentiate Between Ischemic and Nonischemic Dilated Cardiomyopathy19982.571Citations (PDF)
182Acute Coronary Syndromes: Is a Unified Management Strategy Emerging?199812.10Citations (PDF)
183Abciximab in Primary Coronary Angioplasty for Acute Myocardial Infarction Improves Short- and Medium-Term Outcomes.199812.154Citations (PDF)
184Comparison of Cardiac Troponin I, Creatine Kinase-MB, and Myoglobin for Detection of Acute Ischemic Myocardial Injury in a Swine Model.19982.277Citations (PDF)
185Myocardial Cell Death and Apoptosis in Hibernating Myocardium199712.195Citations (PDF)
186Impact of Acute Propranolol Administration on Dobutamine-Induced Myocardial Ischemia as Evaluated by Myocardial Perfusion Imaging and Echocardiography19972.553Citations (PDF)
187Direct Comparison of Arbutamine and Dobutamine Stress Testing With Myocardial Perfusion Imaging and Echocardiography in Patients With Coronary Artery Disease19972.59Citations (PDF)
188Rationale, Design, and Baseline Characteristics of a Trial Comparing Aggressive Lipid Lowering With Atorvastatin Versus Revascularization Treatments (AVERT)19972.531Citations (PDF)
189Coronary Angioplasty Induces a Systemic Inflammatory Response19972.580Citations (PDF)
190Prognostic Importance of Scintigraphic Left Ventricular Cavity Dilation During Intravenous Dipyridamole Technetium-99m Sestamibi Myocardial Tomographic Imaging in Predicting Coronary Events19972.579Citations (PDF)
191Nitroglycerin Enhances the Ability of Dobutamine Stress Echocardiography to Detect Hibernating Myocardium
Circulation, 96, 3992-4001
199724.714Citations (PDF)
192Lessons From Coronary Atherosclerosis "Regression" Trials.19961.49Citations (PDF)
193Review of Cholesterol-Lowering Therapy: Coronary Angiographic and Events Trials19963.221Citations (PDF)
194Recombinant Human Growth Hormone, Insulin-Like Growth Factor 1, and Combination Therapy in AIDS-Associated Wasting199612.9133Citations (PDF)
195Functional and Structural Alterations With 24-Hour Myocardial Hibernation and Recovery After Reperfusion
Circulation, 94, 507-16
199624.763Citations (PDF)
196Effects of Cigarette Smoking on the Angiographic Evolution of Coronary Atherosclerosis
Circulation, 94, 614-21
199624.7101Citations (PDF)
197Percentage Change Rather Than Plasma Level of LDL-Cholesterol Determines Therapeutic Response in Coronary Heart Disease19955.055Citations (PDF)
198Coronary Arteriography19952.00Citations (PDF)
199Antianginal Efficacy and Safety of Controlled-Delivery Diltiazem QD Versus an Equivalent Dose of Immediate-Release Diltiazem TID19954.13Citations (PDF)
200Safety of Dipyridamole Testing in 73,806 Patients: The Multicenter Dipyridamole Safety Study19951.8179Citations (PDF)
201Feasibility of Radiofrequency Powered, Thermal Balloon Ablation of Atrioventricular Bypass Tracts via the Coronary Sinus: In Vivo Canine Studies19951.3128Citations (PDF)
202986-77 Does Atropine Completely Abolish the Influence of β-Blockade on the Ischemic Response During Dobutamine Stress Echocardiography?199512.10Citations (PDF)
203Randomized Double-Blind Comparison of Two Doses of Hirulog With Heparin as Adjunctive Therapy to Streptokinase to Promote Early Patency of the Infarct-Related Artery in Acute Myocardial Infarction
Circulation, 91, 2132-9
199524.7101Citations (PDF)
204Effects of Cholesterol Lowering on the Progression of Coronary Atherosclerosis in Women
Circulation, 92, 2404-10
199524.758Citations (PDF)
205Oral Verapamil Inhibits Platelet Thrombus Formation in Humans.
Circulation, 89, 630-4
199424.742Citations (PDF)
206Endothelium-Derived Nitric Oxide Attenuates Neutrophil Adhesion to Endothelium Under Arterial Flow Conditions.19944.758Citations (PDF)
207A New Look at Coronary Angiograms: Plaque Morphology as a Help to Diagnosis and to Evaluate Outcome19942.08Citations (PDF)
208Plaque Stabilization: A Mechanism for the Beneficial Effect of Lipid-Lowering Therapies in Angiography Studies19949.732Citations (PDF)
209Efficacy of High Dose Intravenous Heparin for Treatment of Left Ventricular Thrombi With High Embolic Risk.199412.158Citations (PDF)
210Localized Intramural Drug Delivery During Balloon Angioplasty Using Hydrogel-Coated Balloons and Pressure-Augmented Diffusion.199412.173Citations (PDF)
211Calcium Channel Blockers and Coronary Atherosclerosis: From the Rabbit to the Real World
American Heart Journal, 128, 1309-1316
19943.435Citations (PDF)
212Are Qualitative Features of Coronary Artery Lesions Useful in Predicting Progression?19940.00Citations (PDF)
213Design Features of a Controlled Clinical Trial to Assess the Effect of an HMG CoA Reductase Inhibitor on the Progression of Coronary Artery Disease19933.413Citations (PDF)
214A Dose-Response Study of Clentiazem, a Chloro-Derivative of Diltiazem, in Patients With Stable Angina199312.19Citations (PDF)
215Methylene Blue Inhibits the Antithrombotic Effect of Nitroglycerin199312.128Citations (PDF)
216Effects of Thrombocytopenia and Shear Rate on Neutrophil and Platelet Deposition on Endothelial and Medial Arterial Surfaces.19934.721Citations (PDF)
217Aspirin Versus Heparin to Prevent Myocardial Infarction During the Acute Phase of Unstable Angina.
Circulation, 88, 2045-8
199324.7290Citations (PDF)
218Progression and Regression of Coronary Atherosclerosis: Data From a Controlled Clinical Trial With Nicardipine19930.02Citations (PDF)
219Reactivation of Unstable Angina After the Discontinuation of Heparin199276.8448Citations (PDF)
220Is Thrombolytic Therapy Striking Out in Unstable Angina?
Circulation, 86, 1642-4
199224.736Citations (PDF)
221Preoperative and Long-Term Cardiac Risk Assessment Predictive Value of 23 Clinical Descriptors, 7 Multivariate Scoring Systems, and Quantitative Dipyridamole Imaging in 360 Patients19926.775Citations (PDF)
222Symptom-Limited Versus Low Level Exercise Testing Before Hospital Discharge After Myocardial Infarction199212.163Citations (PDF)
223Prognostic Implications of a Negative Dipyridamole-Thallium Scan: Results in 360 Patients19923.210Citations (PDF)
224Measuring Progression and Regression of Coronary Atherosclerosis in Clinical Trials: Problems and Progress19922.035Citations (PDF)
225Preoperative Coronary Artery Disease Risk Stratification Based on Dipyridamole Imaging and a Simple Three-Step, Three-Segment Model for Patients Undergoing Noncardiac Vascular Surgery or Major General Surgery19922.597Citations (PDF)
226Effect of Diltiazem Slow-Release Formulation on Silent Myocardial Ischemia in Stable Coronary Artery Disease19922.516Citations (PDF)
227Percutaneous Mitral Valvuloplasty in Surgical High Risk Patients199112.136Citations (PDF)
228Multivariate Clinical Models and Quantitative Dipyridamole-Thallium Imaging to Predict Cardiac Morbidity and Death After Vascular Reconstruction19913.472Citations (PDF)
229Regression of Coronary Atherosclerosis: An Achievable Goal? Review of Results From Recent Clinical Trials19913.217Citations (PDF)
230Clinical and Angiographic Features and Prognostic Significance of Early Postinfarction Angina With and Without Electrocardiographic Signs of Transient Ischemia19913.218Citations (PDF)
231Role of Diltiazem in the Treatment of Silent Myocardial Ischemia19912.52Citations (PDF)
232Newer Concepts in the Treatment of Unstable Angina Pectoris19912.58Citations (PDF)
233Proischemic Complications of Dihydropyridine Calcium Channel Blockers.
Circulation, 84, 2598-600
199124.768Citations (PDF)
234Diltiazem at Reperfusion Reduces Neutrophil Accumulation and Infarct Size in Dogs With Ischaemic Myocardium.199113.523Citations (PDF)
235Hemodynamic, Platelet and Clinical Responses to Prostacyclin in Unstable Angina Pectoris19902.513Citations (PDF)
236What Is an Antiarrhythmic Drug? From Clinical Trials to Fundamental Concepts19902.517Citations (PDF)
237Transient Left Ventricular Cavitary Dilation During Dipyridamole-Thallium Imaging as an Indicator of Severe Coronary Artery Disease19902.568Citations (PDF)
238Effects of Nitroglycerin at Therapeutic Doses on Platelet Aggregation in Unstable Angina Pectoris and Acute Myocardial Infarction19902.5145Citations (PDF)
239Postoperative Myocardial Infarction and Cardiac Death: Predictive Value of Dipyridamole-Thallium Imaging and Five Clinical Scoring Systems Based on Multifactorial Analysis19906.762Citations (PDF)
240A Controlled Clinical Trial to Assess the Effect of a Calcium Channel Blocker on the Progression of Coronary Atherosclerosis.
Circulation, 82, 1940-53
199024.7388Citations (PDF)
241Left-to-Right Atrial Shunting After Percutaneous Mitral Valvuloplasty. Incidence and Long-Term Hemodynamic Follow-Up.
Circulation, 81, 1190-7
199024.794Citations (PDF)
242Is Dipyridamole-Thallium Imaging Preferable to Submaximal Exercise Thallium Testing for Risk Stratification After Thrombolysis?19903.46Citations (PDF)
243Influence of Fibrinolysis and Percutaneous Transluminal Coronary Angioplasty on the Frequency of Ventricular Premature Complexes19892.525Citations (PDF)
244Comparison by Quantitative Angiographic Assessment of Coronary Stenoses of One View Showing the Severest Narrowing to Two Orthogonal Views19892.562Citations (PDF)
245Usefulness of the Severity and Extent of Reversible Perfusion Defects During Thallium-Dipyridamole Imaging for Cardiac Risk Assessment Before Noncardiac Surgery19892.583Citations (PDF)
246Acute Pulmonary Edema Caused by Prolonged Myocardial Stunning After Dipyridamole-Thallium Imaging19893.211Citations (PDF)
247Limited Usefulness of Intermittent Nitroglycerin Patches in Stable Angina198912.149Citations (PDF)
248Acute Pulmonary Edema Caused by Prolonged Myocardial Stunning After Dipyridamole-Thallium Imaging19893.21Citations (PDF)
249Treatment of Recurrent Restenosis With Repeat Percutaneous Transluminal Coronary Angioplasty19882.516Citations (PDF)
250Massive Mitral Regurgitation Caused by Tearing of the Anterior Leaflet During Percutaneous Mitral Balloon Valvuloplasty19883.221Citations (PDF)
251Aspirin, Heparin, or Both to Treat Acute Unstable Angina198876.81,249Citations (PDF)
252Regression of Coronary Atherosclerosis
Drugs, 36, 37-42
198815.52Citations (PDF)
253Restenosis and Progression of Coronary Atherosclerosis After Coronary Angioplasty198812.152Citations (PDF)
254Multiple Coronary Angioplasty: A Model to Discriminate Systemic and Procedural Factors Related to Restenosis198812.192Citations (PDF)
255Long-Term Prognosis After Myocardial Infarction in Patients With Previous Coronary Artery Bypass Surgery198812.150Citations (PDF)
256Pathophysiology of Unstable Angina Pectoris: Clinical, Angiographic and Therapeutic Observations19880.00Citations (PDF)
257Design Features of a Controlled Clinical Trial to Assess the Effect of a Calcium Entry Blocker Upon the Progression of Coronary Artery Disease19873.439Citations (PDF)
258Comparative Antianginal Effects of Nisoldipine and Nifedipine in Patients With Chronic Stable Angina19873.418Citations (PDF)
259Uncomplicated Non-Q Wave Infarction Caused by Total Obstruction of the Left Main Coronary Artery
American Heart Journal, 113, 1224-1226
19873.48Citations (PDF)
260‘Second Generation’ Dihydropyridine Calcium Antagonists
Drugs, 34, 578-598
198715.586Citations (PDF)
261Early Results, Complications and Restenosis Rates After Multilesion and Multivessel Percutaneous Transluminal Coronary Angioplasty19872.529Citations (PDF)
262Previous Coronary Artery Bypass Grafting as an Adverse Prognostic Factor in Unstable Angina Pectoris19862.538Citations (PDF)
263Long-Term Reproducibility and Significance of Provokable Ventricular Arrhythmias After Myocardial Infarction198612.142Citations (PDF)
264Exercise Testing After Myocardial Infarction: A Perspective198612.12Citations (PDF)
265Percutaneous Transluminal Coronary Angioplasty for the Treatment of Variant Angina198512.157Citations (PDF)
266Comparison of Clinical Variables and Variables Derived From a Limited Predischarge Exercise Test as Predictors of Early and Late Mortality After Myocardial Infarction198512.1120Citations (PDF)
267Coronary Angiographic Significance of Left Anterior Fascicular Block During Acute Myocardial Infarction198512.127Citations (PDF)
268A Dose-Ranging, Placebo-Controlled, Double-Blind Trial of Nisoldipine in Effort Angina: Duration and Extent of Antianginal Effects198512.156Citations (PDF)
269Serial Exercise Testing in Patients With Effort Angina: Variable Tolerance, Fixed Threshold198512.152Citations (PDF)
270A Randomized Study Comparing Propranolol and Diltiazem in the Treatment of Unstable Angina198512.1151Citations (PDF)
271Factors Associated With Progression of Coronary Artery Disease in Patients With Normal or Minimally Narrowed Coronary Arteries19852.557Citations (PDF)
272Exercise Testing in the Early Period After Myocardial Infarction in the Evaluation of Prognosis19841.43Citations (PDF)
273Is Progression of Coronary Artery Disease Occurring at Bouts or as a Continuous Process? Serial Cineangiographic Studies in 44 Patients19840.97Citations (PDF)
274Clinical and Angiographic Factors Associated With Coronary Artery Disease Progression of Coronary Artery Disease198412.195Citations (PDF)
275Myocardial Infarction in Patients With Previous Coronary Artery Bypass Surgery198412.118Citations (PDF)
276Ventricular Arrhythmias During Ergonovine-Induced Episodes of Variant Angina19843.428Citations (PDF)
277Circadian Variation in Variant Angina19842.5124Citations (PDF)
278Calcium Antagonists
Drugs, 25, 178-195
198315.552Citations (PDF)
279The Ergonovine Test — To Catch a Leprechaun19833.20Citations (PDF)
280Sudden Death in Two Patients With Variant Angina and Apparently Minimal Fixed Coronary Stenoses19831.511Citations (PDF)
281Spontaneous Remission Is a Frequent Outcome of Variant Angina198312.171Citations (PDF)
282Unstable Angina and Progression of Coronary Atherosclerosis198376.8243Citations (PDF)
283Symptomatic Coronary Artery Spasm Following Radiotherapy for Hodgkin's Disease
Chest, 83, 284-285
19835.927Citations (PDF)
284Clinical Characteristics of Patients With Variant Angina Complicated by Myocardial Infarction or Death Within 1 Month19822.555Citations (PDF)
285Clinical Manifestations and Pathophysiology of Myocardial Ischemia With Special Reference to Coronary Artery Spasm and the Role of Slow Channel Calcium Blockers19829.715Citations (PDF)
286S-T Segment Elevation and Coronary Spasm in Response to Exercise19812.549Citations (PDF)
287Ergonovine Testing to Detect Spontaneous Remissions of Variant Angina During Long-Term Treatment With Calcium Antagonist Drugs19812.5113Citations (PDF)
288Provocative Testing With Ergonovine to Assess the Efficacy of Treatment With Nifedipine, Diltiazem and Verapamil in Variant Angina19812.5106Citations (PDF)
289Is Variant Angina the Coronary Manifestation of a Generalized Vasospastic Disorder?198176.8268Citations (PDF)
290Hemodynamics and Coronary Flow Following Diltiazem Administration in Anesthetized Dogs and in Humans
Chest, 78, 224-230
19805.986Citations (PDF)
291Hemodynamics and Coronary Flow Following Diltiazem Administration in Anesthetized Dogs and in Humans
Chest, 78, 224-230
19805.971Citations (PDF)
292Hemodynamic Effects of a Single Oral Dose of Nifedipine Following Acute Myocardial Infarction.
Chest, 78, 574-9
19805.931Citations (PDF)
293Refractory Variant Angina Controlled With Combined Drug Therapy in a Patient With a Single Coronary Artery19800.79Citations (PDF)
294Ergonovine Testing in a Coronary Care Unit19802.594Citations (PDF)
295Prognostic Value of Exercise Testing Soon After Myocardial Infarction197976.8726Citations (PDF)
296Recurrence of Prinzmetal Angina Seven Years Following Aortocoronary Bypass Surgery: A Clinical and Angiographic Follow-Up19790.75Citations (PDF)
297Chronic Oral Vasodilator Therapy to Control Heart Failure in Postinfarction Ventricular Septal Defect19790.70Citations (PDF)
298Clinical Predictors of Angina Following Myocardial Infarction19793.234Citations (PDF)
299Left Main Coronary Artery Stenosis in Young Patients
Chest, 76, 508-513
19795.912Citations (PDF)
300Hospital Treatment of Congestive Heart Failure: Management According to Hemodynamic Profile19783.270Citations (PDF)
301Coronary Artery Disease in Young Women: Clinical and Angiographic Features and Correlation With Risk Factors19782.556Citations (PDF)
302Myocardial Ischemia: Detection and Quantitation197812.913Citations (PDF)
303Aortic and Mitral Valve Replacement in a Patient With Osteogenesis Imperfecta
Chest, 72, 363-364
19775.916Citations (PDF)
304Early Changes in Regional and Global Left Ventricular Function Induced by Graded Reductions in Regional Coronary Perfusion19772.5183Citations (PDF)
305Regional Mechanical Function in Acute Myocardial Ischemia19770.50Citations (PDF)
306Cardiac Features of an Unusual X-Linked Humeroperoneal Neuromuscular Disease197576.892Citations (PDF)
307Long-Term Prognosis of Patients With Incomplete Bilateral Bundle Branch Block Complicating Acute Myocardial Infarction: Role of Cardiac Pacing19742.536Citations (PDF)